Hidrasec Junior (Racecadotril)

Hidrasec Junior is indicated for the short‑term treatment of acute watery diarrhea in children. It helps to control stool output and supports rehydration efforts.

• Management of acute watery diarrhea in pediatric patients
• Adjunct to oral rehydration therapy
• Reducing stool frequency and volume
• Supporting fluid and electrolyte balance during diarrheal episodes
• May be used in community or clinical settings where rapid symptom control is needed

• Racecadotril acts as an inhibitor of intestinal enkephalinase, the enzyme that degrades endogenous enkephalins. By preventing this breakdown, the drug increases local enkephalin concentrations, which bind to opioid receptors in the gut wall. This interaction reduces hypersecretion of electrolytes and water and slows intestinal motility, thereby limiting the volume of diarrheal output without affecting systemic opioid pathways.

Adverse reactions to Hidrasec Junior are generally mild, but monitoring is advised.

Common

• Mild abdominal discomfort
• Nausea
• Transient headache
• Slight increase in constipation risk
• Mild skin rash or itching

Serious

• Severe allergic reaction (anaphylaxis)
• Persistent vomiting
• Marked abdominal pain or bloating
• Signs of hepatic dysfunction (rare)
• Severe rash with blistering (Stevens‑Johnson syndrome)

Before using Hidrasec Junior, consider the following safety points.

• Verify the child's age and weight to ensure appropriate use
• Assess for known hypersensitivity to racecadotril or excipients
• Use caution in patients with pre‑existing liver disease
• Monitor for signs of dehydration despite treatment
• Avoid use if the diarrhea is caused by bacterial infection requiring antibiotics
• Consult a healthcare professional if diarrhea persists beyond 48‑72 hours
• Keep the medication out of reach of children to prevent accidental ingestion

Potential drug interactions should be reviewed prior to initiating therapy.

Avoid

• Concomitant use with potent opioid agonists that may mask gastrointestinal effects
• Combination with medications that significantly alter gut motility (e.g., prokinetics)

Use with caution

• Antacids that may affect absorption of oral formulations
• Drugs metabolized by hepatic enzymes that could be inhibited by racecadotril metabolites
• Concurrent use of other antidiarrheal agents (e.g., loperamide) to avoid excessive reduction of gut motility
• Herbal supplements affecting gastrointestinal function